

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Administration for Children and Families****Fiscal year 1999 Discretionary Announcement for University-Head Start Partnerships and Head-Start Research Scholars; Availability of Funds and Request for Proposals**

AGENCY: Administration on Children, Youth and Families, ACF, DHHS.

ACTION: Notice.

SUMMARY: The Administration for Children and Families, Administration on Children, Youth and Families, Head Start Bureau announces the availability of funds for two Priority Areas; University-Head Start Partnerships (1.01) and Head Start Research Scholars (1.02). These priority areas will support research activities in the areas of infant and toddler development within the cultural context, the promotion of mental health in Head Start and Early Head Start, family literacy or field-initiated research which will increase our knowledge of low-income children's development for the purpose of improving services or have significant policy implications.

DATES: The closing date for receipt of applications is 5:00 P.M. EDT June 14, 1999.

ADDRESSES: Applications, including all necessary forms can be downloaded from the Head Start web site at www.acf.dhhs.gov/programs/hsb. The web site also contains a listing of all Head Start and Early Start programs.

Hard copies of the application may be obtained by writing or calling the Operations Center or sending an e-mail to hsr@lcgnet.com.

FOR FURTHER INFORMATION CONTACT: ACYF Operations Center at: 1815 N. Fort Meyer Drive Suite 300, Arlington, Virginia 22209 or (1-800) 351-2293.

SUPPLEMENTARY INFORMATION:**Priority Areas****Priority Area 1.01 University-Head Start Partnerships**

Eligible Applicants: Universities and four-year colleges on behalf of a faculty member who holds a doctorate or equivalent in their respective field.

Project Duration: The announcement for Priority Area 1.01 is soliciting applications for project periods of three years with the first year as a planning grant. However, requests for project periods of four or five years will be considered if the applicant can make a strong justification for the need for a

longer project period in order to complete the research. It should be noted that requests for longer project periods will only be granted in only rare instances. Awards, on a competitive basis, will be for the first one-year planning budget period. Applications for continuation funds under these awards beyond the first-year budget period, but within the established project period, will be entertained in subsequent years on a noncompetitive basis, subject to availability of funds, satisfactory progress of the grantee, and a determination that continued funding would be in the best interests of the Government.

Federal Share of Project Costs: The maximum Federal share is \$75,000 for the first-year budget period. The Federal share for the subsequent years is approximately \$150,000 for each year of the project period. The Federal Share is inclusive of indirect costs.

Anticipated Number of Projects to be Funded: It is anticipated that 4-6 projects will be funded.

Priority Area 1.02 Head Start Research Scholars

Eligible Applicants: Institutions of higher education on behalf of graduate students who have been accepted into a doctoral program in the field of the proposed study and have completed their Master's degree or equivalent in that field prior to applying for this grant or by the time grants are awarded and have sent formal notification of having been granted the degree to ACYF. To be eligible to administer the grant on behalf of the student, the institution must be fully accredited by one of the regional accrediting commissions recognized by the Department of Education and the Council on Post-Secondary Accreditation. In addition, the specific graduate student on whose behalf the application is made must be identified and any resultant grant award if not transferable to another student.

Project Duration: The announcement for Priority Area 1.02 is soliciting applications for project periods up to two years. Awards, on a competitive basis, will be for a one-year budget period, although project periods may be for two years. It should be noted, that if the graduate student, on whose behalf the university is applying, expects to receive a doctorate by the end of the first year budget period, the applicant should request a one-year project period only. A second year budget period will not be granted if the student has graduated by the end of the first year. Applications for continuation grants will be entertained in the subsequent year on a non-competitive basis, subject

to availability of funds, satisfactory progress of the grantee and a determination that continued funding would be in the best interest of the Government

Federal Share of Project Costs: The maximum Federal share is not to exceed \$15,000 for the first-year budget period or a maximum of \$30,000 for a two-year project period.

Anticipated Number of Projects to be Funded: It is anticipated that 10 projects will be funded. No university will be funded for more than one candidate, unless there are no other approved applications.

Statutory Authority: The Head Start Act, as amended 42 U.S.C. 9801 *et seq.*

Dated: April 8, 1999.

James A. Harrell,

Deputy Commissioner, Administration on Children, Youth and Families.

[FR Doc. 99-9187 Filed 4-12-99; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[Docket No. 99N-0486]

Physician Labeling and Patient Labeling for Progestational Drug Products; Warnings and Contraindications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it intends to revoke previously issued guidance texts for physician labeling and patient labeling for progestational drug products that were published in the **Federal Register** of January 12, 1989 (54 FR 1243). The reasons for revoking the guidance texts are discussed in a notice of proposed rulemaking on progestational drug products that appears elsewhere in this issue of the **Federal Register**.

DATES: Written comments by July 12, 1999.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Diane V. Moore, Center for Drug Evaluation and Research (HFD-580), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4260.

Dated: March 25, 1999.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 99-9147 Filed 4-12-99; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, University of Texas SPORE in Lung Cancer.

Date: April 26, 1999.

Time: 2:00 PM to 5:00 PM.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, National Cancer Institute, 6130 Executive Boulevard, 6th Floor, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Maureen Johnson, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd., Bethesda, MD 20892-7408, 301-496-2378. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 6, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-9104 Filed 4-12-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 1), notice is hereby given of the meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

A portion of the meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended because the premature disclosure of discussions would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Date: April 19-20, 1999.

Open: April 19, 1999, 9:00 a.m., to 5:00 p.m.

Agenda: Director's Report; DCLG-NCI Communications Initiative; Consumer Involvement in Peer Review.

Place: National Institutes of Health, Natcher Conference Center, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Eleanor Nealon, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institute, Building 31, Room 10A06, Bethesda, MD 20892-2580, (301) 594-3194.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Open: April 20, 1999, 9:00 a.m. to 4:15 p.m.

Agenda: Communications Initiatives; Mechanisms for Ongoing Feedback from the Advocacy Community; Future Plans for DCLG.

Place: National Institutes of Health, Natcher Conference Center, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Eleanor Nealon, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institute, Building 31, Room 10A06, Bethesda, MD 20892-2580, (301) 594-3194.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Closed: April 20, 1999, 4:15 p.m. to 5:00 p.m.

Agenda: Personnel Issues Related to Committee Membership.

Place: National Institutes of Health, Natcher Conference Center, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Eleanor Nealon, Executive Secretary, Office of Liaison Activities, National Institutes of Health, National Cancer Institute, Building 31, Room 10A06, Bethesda, MD 20892-2580, (301) 594-3194.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 1, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-9108 Filed 4-12-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Advisory Council.

Date: May 20-21, 1999.

Open: May 20, 1999, 8:30 a.m. to 2:00 p.m.

Agenda: For discussion of program policies and issues.

Place: National Institutes of Health, Building 31, C wing, Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

Closed: May 20, 1999, 2:00 p.m. to adjournment.